Guerbet SA
4G8
Company Profile
Business description
Guerbet SA is a healthcare company that manufactures and markets medical imaging contrast agents destined for diagnostic purposes. Its products include medical imaging contrast products for x-ray imaging, magnetic resonance imaging, ultrasound imaging and for nuclear medicine. The company markets its products under the brand names such as Xenetix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol.
Contact
15 rue des Vanesses
Zone Paris Nord II
Villepinte93420
FRAT: +33 145915000
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
2,746
Stocks News & Analysis
stocks
The ASX data center stock flying under the radar
While markets chase AI hype, this data centre company offers real data center earnings and a visible growth pipeline.
stocks
What did Morningstar subscribers buy and sell during June?
ETFs took centre stage in June alongside renewed interest in beaten down growth names.
stocks
Australia’s largest gold miner downgraded on a falling gold price
A cooling gold price sees fair value cuts across the board.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,025.90 | 24.70 | -0.27% |
| CAC 40 | 8,366.85 | 2.20 | 0.03% |
| DAX 40 | 25,147.03 | 32.78 | 0.13% |
| Dow JONES (US) | 52,508.27 | 9.63 | 0.02% |
| FTSE 100 | 10,529.39 | 31.10 | 0.30% |
| HKSE | 24,695.62 | 354.89 | 1.46% |
| NASDAQ | 26,107.01 | 233.83 | 0.90% |
| Nikkei 225 | 68,554.30 | 810.80 | 1.20% |
| NZX 50 Index | 13,595.52 | 55.70 | -0.41% |
| S&P 500 | 7,543.59 | 28.25 | 0.38% |
| S&P/ASX 200 | 8,830.30 | 26.70 | -0.30% |
| SSE Composite Index | 3,963.90 | 3.22 | -0.08% |